Supporting Information

Inhibitors of Human Divalent Metal Transporters DMT1 (SLC11A2) and ZIP8 (SLC39A8) from a GDB-17 Fragment Library

Jonai Pujol-Giménez, Marion Poirier, Sven Bühlmann, Céline Schuppisser, Rajesh Bhardwaj, Mahendra Awale, Ricardo Visini, Sacha Javor, Matthias A. Hediger,* and Jean-Louis Reymond*
Supporting Information

Table of contents

Analogs of rac-3 .................................................................................................................. 2
Chemistry ............................................................................................................................ 3
HPLC purity of final compounds ........................................................................................ 13
$^1$H and $^{13}$C NMR spectra ............................................................................................ 14
Complexation attempts with rac-3 .................................................................................... 35
Selected IC$_{50}$ curves for inhibition of ZIP8 .................................................................. 36
**Analogs of rac-3**

![Chemical structures of analogs of rac-3](image)

*Figure S1.* Analogs of compound rac-3 tested for ZIP8 inhibition. The % inhibition observed is in the ZIP8 screening given, as well as the IC$_{50}$ value when measured.
All reagents were purchased from commercial sources and were used without further purification. Flash chromatography purifications were performed with silica Gel 60 (Sigma, 0.040–0.063 mm, 230–400 mesh ASTM). Low resolution mass spectra were obtained by electron spray ionization (ESI-MS) in the positive mode on a Thermo Scientific LCQ Fleet. High resolution mass spectra were obtained by electron spray ionization (HR-ESI-MS) in the positive mode recorded on a Thermo Scientific LTQ Orbitrap XL. $^1$H and $^{13}$C-NMR spectra were measured on a Bruker Avance 300 spectrometer (at 300 MHz and 75 MHz, respectively) or on a Bruker Avance II 400 spectrometer (at 400 MHz and 101 MHz, respectively). $^1$H and $^{13}$C chemical shifts are given in ppm (δ) relative to the solvent proton impurity signals, and resonance multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), and m (multiplet); br = broad peak. Compound purities were assessed by analytical reversed phase HPLC (RP-HPLC) at a detection wavelength of 214 nm. Analytical RP-HPLC was performed on a Dionex Ultimate 3000 RSLC System (DAD-3000 RS Photodiode Array Detector) using a Dionex Acclaim RSLC 120 column (C18, 3.0 x 50 mm, particle size 2.2 μm, 120 Å pore size) and a flow rate of 1.2 mL min$^{-1}$. Data were recorded and processed with Xcalibur (version 2.2, Thermo Scientific). Eluents for analytical RP-HPLC were as follows: (A) milliQ-deionized water containing 0.05% TFA, (D) HPLC-grade acetonitrile/milliQ-deionized water (9:1) containing 0.05% TFA. Conditions for analytical RP-HPLC were as follows: in 2.2 min from 100 % A to 100 % D, then staying on 100 % D (method A), in 7.5 min from 100 % A to 100 % D, then staying on 100 % D (method B). Optical rotations were recorded in cells with 10 cm path length on a Polartronic H532 (Gerber Instruments) digital polarimeter. Preparative RP-HPLC were performed with a Waters Prep LC System Controller with a Dr. Maisch GmbH Reprospher column (C18-DE, 100×30 mm, particle size 5 μm, pore size 100 Å, flow rate 40 mL/min). Compounds were detected by UV absorption at 214 nm using Waters 2489 UV/Vis detector. The elution solutions were: (A) MilliQ deionized water containing 0.1% TFA; (D) MilliQ deionized water / acetonitrile (10 / 90) containing 0.1% TFA. Commercial compounds were purchased as 1 mg solid and dissolved in DMSO to get a 10 mM stock solution that was used for screening. The purity of the most active compounds was checked by LC-MS and they were purchased in higher amount (usually 25 mg) and analysed by NMR and HR-MS. The purity was determined by RP-UPLC at 214 nm.
4-((trifluoromethyl)sulfonyl)phenol (1a): Compound 1a was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 4.67 \text{ min (method B)} \). \(^1\)H NMR (300 MHz, DMSO): \( \delta 11.49 \) (1H, br s), 8.03 – 7.83 (2H, m), 7.24 – 7.02 (2H, m). \(^{13}\)C NMR (101 MHz, DMSO): \( \delta 165.8 \), 133.3 (CH\text{ar}), 119.6 (q, \( J = 325.9 \) Hz, CF\text{3}), 117.9, 117.0 (CH\text{ar}). HR-MS calculated for C\text{7}H\text{4}F\text{3}O\text{3}S: \( m/z \) 224.9839, \( m/z \) found 224.0004.

4-((trifluoromethyl)sulfonyl)aniline (1b): Compound 1b was purchased as a 25 mg solid form from Enamine. RP-UPLC: \( t_R = 2.24 \text{ min (method A)} \). \(^1\)H NMR (300 MHz, DMSO): \( \delta 7.69 – 7.56 \) (2H, m), 6.92 (2H, s), 6.81 – 6.70 (2H, m). HR-MS calculated for C\text{7}H\text{7}O\text{2}NF\text{3}S: \( m/z \) 226.0144, \( m/z \) found 226.9790.

2,4-bis((trifluoromethyl)sulfonyl)phenol (1c): Compound 1c was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 2.41 \text{ min (method A)} \). HR-MS calculated for C\text{8}H\text{3}F\text{6}O\text{5}S\text{2}: \( m/z \) 356.9332, \( m/z \) found 356.9323.

4-(methylsulfonyl)phenol (1d): Compound 1d was purchased as a 25 mg solid form from Alpha Aesar. RP-UPLC: \( t_R = 1.43 \text{ min (method A)} \). \(^1\)H NMR (300 MHz, DMSO): \( \delta 10.56 \) (1H, s), 7.81 – 7.64 (2H, m), 7.04 – 6.84 (2H, m), 3.11 (3H, s). HR-MS calculated for C\text{7}H\text{5}O\text{3}S: \( m/z \) 171.0121, \( m/z \) found 171.0128.

2-fluoro-4-(methylsulfonyl)phenol (1e): Compound 1e was purchased as a 1 mg solid form from Ambiter. RP-UPLC: \( t_R = 1.48 \text{ min (method A)} \). HR-MS calculated for C\text{7}H\text{6}F\text{3}O\text{3}S: \( m/z \) 189.0027, \( m/z \) found 189.0025.

N-(5-(ethylsulfonyl)-2-hydroxyphenyl)methanesulfonamide (1f): Compound 1f was purchased as a 1 mg solid form from Ambiter. RP-UPLC: \( t_R = 1.72 \text{ min (method A)} \). HR-MS calculated for C\text{9}H\text{12}NO\text{5}S\text{2}: \( m/z \) 278.0162, \( m/z \) found 278.0157.

N-(5-(ethylsulfonyl)-2-hydroxyphenyl)isobutyramide (1g): Compound 1g was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 1.78 \text{ min (method A)} \). HR-MS calculated for C\text{12}H\text{18}NO\text{4}S: \( m/z \) 272.0951, \( m/z \) found 272.0949.

N-(5-(ethylsulfonyl)-2-hydroxyphenyl)-2-methylcyclopropane-1-carboxamide (1h): Compound 1h was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 1.89 \text{ min (method A)} \). HR-MS calculated for C\text{13}H\text{18}NO\text{4}S: \( m/z \) 284.0951, \( m/z \) found 284.0948.
4-hydroxybenzenesulfonamide (1i): Compound 1i was purchased as a 25 mg solid form from Acros organics. RP-UPLC: \( t_R = 1.17 \) min (method A). \(^1\)H NMR (300 MHz, DMSO): \( \delta 7.79 – 7.54 \) (2H, m), 7.08 (2H, br s), 6.99 – 6.73 (2H, m). HR-MS calculated for C\(_6\)H\(_6\)NO\(_3\)S: \( m/\text{z} \) 172.0074, \( m/\text{z} \) found 172.0079.

4,4'-sulfonyldiphenol (1j): Compound 1j was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 1.73 \) min (method A). HR-MS calculated for C\(_{12}\)H\(_{11}\)O\(_4\)S: \( m/\text{z} \) 251.0373, \( m/\text{z} \) found 251.0371.

3,5-dichloro-4-hydroxybenzenesulfonic acid (1k): Compound 1k was purchased as a 1 mg solid form from Ambiter. RP-UPLC: \( t_R = 1.11 \) min (method A). HR-MS calculated for C\(_6\)H\(_3\)Cl\(_2\)O\(_4\)S: \( m/\text{z} \) 240.9135, \( m/\text{z} \) found 240.9132.

sodium 4,4'-sulfonylbis(2,6-dichlorophenolate) (1l): Compound 1l was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 2.30 \) min (method A). HR-MS calculated for C\(_{12}\)H\(_4\)Cl\(_4\)O\(_4\)S: \( m/\text{z} \) 384.8668, \( m/\text{z} \) found 384.9348.

2-chloro-4-(morpholinosulfonyl)phenol (1m): Compound 1m was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 1.90 \) min (method A). HR-MS calculated for C\(_{10}\)H\(_{11}\)ClNO\(_4\)S: \( m/\text{z} \) 276.0103, \( m/\text{z} \) found 276.0099.

2-hydroxy-5-(pyrrolidin-1-ylsulfonyl)benzamide (1n): Compound 1n was purchased as a 1 mg solid form from Enamine. RP-UPLC: \( t_R = 1.83 \) min (method A). HR-MS calculated for C\(_{11}\)H\(_{13}\)N\(_2\)O\(_4\)S: \( m/\text{z} \) 269.0602, \( m/\text{z} \) found 269.0599.

5-methyl-4,5,6,7-tetrahydrobenzo[\( b \)]thiophene-2-carboxylic acid (2): Compound 2 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 2.21 \) min (method A). \(^1\)H NMR (300 MHz, DMSO): \( \delta 12.76 \) (1H, s), 7.39 (1H, s), 2.97 – 2.57 (3H, m), 2.14 (1H, dd, \( J = 15.9, 10.0 \) Hz), 1.94 – 1.65 (2H, m), 1.39 (1H, m), 1.02 (3H, d, \( J = 6.5 \) Hz). \(^{13}\)C NMR (101 MHz, DMSO): \( \delta 163.0, 142.8, 136.4, 133.6 \) (CH\(_{ar}\)), 130.6, 33.1 (CH\(_2\)), 30.8 (CH\(_2\)), 28.3 (CH), 24.5 (CH\(_2\)), 21.2 (CH\(_3\)). HR-MS calculated for C\(_{10}\)H\(_{13}\)O\(_2\)S: \( m/\text{z} \) 197.0631, \( m/\text{z} \) found 197.0629.

6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine, HCl salt (rac-3): Compound rac-3 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 1.83 \) min (method A). \(^1\)H NMR (300 MHz, MeOD): \( \delta 7.48 \) (1H, d, \( J = 2.0 \) Hz, H\(_{ar}\)), 7.36 (1H, d, \( J = 8.7 \) Hz, H\(_{ar}\)), 7.14 (1H, dd, \( J = 8.7, 2.1 \) Hz, H\(_{ar}\)), 4.61 (1H, t, \( J = 4.9 \) Hz), 2.88 – 2.63 (2H, m),
2.33 – 2.19 (1H, m), 2.14 – 1.93 (3H, m). $^{13}$C NMR (101 MHz, MeOD): $\delta$ 136.7, 130.7, 129.0, 126.2, 124.1 (CH$_{ar}$), 119.2 (CH$_{ar}$), 114.9, 113.7 (CH$_{ar}$), 45.9 (CH), 29.3 (CH$_2$), 21.3 (CH$_2$), 20.0 (CH$_2$). HR-MS calculated for C$_{12}$H$_{11}$ClN: m/z 204.0575, m/z found 204.0571.

(S)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine, HCl salt ((S)-3): Compound (S)-7 (126 mg, 0.32 mmol, 1.0 eq) was suspended in DCM (2 mL) in a two-necks flask. BCl$_3$ (0.81 mL, 1 M in DCM, 0.81 mmol, 3.0 eq) was added dropwise. The solution was stirred at room temperature for 5 h and then at 10 °C for 15 h. KOH (7 mL, 20% w/v) was slowly added dropwise with the temperature kept at 10 °C. The solution was then warmed up to room temperature. The two phases were separated. The aqueous phase was extracted twice with 10 mL 9/1 DCM/MeOH. The combined organic layers were washed with brine, dried over Na$_2$SO$_4$ and concentrated. The residue was purified by column chromatography on silica gel (gradient MeOH / DCM). The residue was dissolved in HCl 1.25 M in MeOH, and the white precipitate was removed. The solvent was removed to afford (S)-3 (51 mg, 0.15 mmol, 47%) as a brownish solid. $\alpha_D$ = -1.3 (c 0.053, MeOH). RP-UPLC: $t_R$ = 1.85 min (method A). $^1$H NMR (400 MHz, MeOD): $\delta$ 7.48 (1H, dd, $J$ = 2.1, 0.6 Hz), 7.36 (1H, dd, $J$ = 8.6, 0.6 Hz), 7.14 (1H, dd, $J$ = 8.7, 2.1 Hz), 4.61 (1H, t, $J$ = 5.0 Hz), 2.88 – 2.77 (1H, m), 2.75 – 2.66 (1H, m), 2.34 – 2.21 (1H, m), 2.16 – 1.91 (2H, m). $^{13}$C NMR (101 MHz, MeOD): $\delta$ 136.7, 130.7, 129.0, 126.2, 124.1 (CH$_{ar}$), 119.2 (CH$_{ar}$), 114.9 (CH$_{ar}$), 113.7, 45.9 (CH), 29.3 (CH$_2$), 21.3 (CH$_2$), 20.1 (CH$_2$). HR-MS calculated for C$_{12}$H$_{11}$ClN: m/z 204.0575, m/z found 204.0573.

(R)-6-chloro-2,3,4,9-tetrahydro-1H-carbazol-1-amine, HCl salt ((R)-3): The procedure described above for (S)-3 was applied starting from (R)-7 (82 mg, 0.21 mmol, 1.0 eq) to afford (R)-3 (18 mg, 0.070 mmol, 33%) as a brownish solid, $\alpha_D$ = 1.03 (c 0.053, MeOH). RP-UPLC: $t_R$ = 1.84 min (method A). $^1$H NMR (300 MHz, MeOD): $\delta$ 7.37 (1H, d, $J$ = 2.0 Hz), 7.36 (1H, dd, $J$ = 8.6, 2.1 Hz), 4.13 – 4.07 (1H, m), 2.72 – 2.63 (2H, m), 2.24 – 2.16 (1H, m), 2.11 – 2.02 (1H, m), 1.90 – 1.67 (2H, m). $^{13}$C NMR (101 MHz, MeOD): $\delta$ 139.6, 136.2, 129.7, 125.3, 122.2 (CH$_{ar}$), 118.5 (CH$_{ar}$), 112.9 (CH$_{ar}$), 111.1, 46.5 (CH), 34.0 (CH$_2$), 22.1 (CH$_2$), 21.9 (CH$_2$). HR-MS calculated for C$_{12}$H$_{14}$ClN$_2$: m/z 221.0840, m/z found 221.0833.

6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine (4): Compound 4 was purchased as a 25 mg solid form from Enamine. RP-UPLC: $t_R$ = 1.89 min (method A). $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ 8.36 (1H, s), 7.58 (1H, d, $J$ = 1.8 Hz), 7.23 – 7.16 (2H, m), 4.08 – 4.04 (1H, m), 2.67 – 2.63 (2H, m), 2.24 – 2.16 (1H, m), 2.06 – 1.99 (1H, m), 1.89 – 1.72 (1H, m), 1.63 – 1.54 (1H, m), 1.48 (2H, s). $^{13}$C NMR (101 MHz, CDCl$_3$): $\delta$ 138.6, 134.6, 129.5, 124.4 (CH), 121.2 (CH), 114.1 (CH$_{ar}$), 113.5 (CH$_{ar}$), 112.2 (CH$_{ar}$), 111.3, 46.5 (CH), 34.0 (CH$_2$), 22.1 (CH$_2$), 21.9 (CH$_2$). HR-MS calculated for C$_{12}$H$_{14}$BrClN$_2$: m/z 277.0354, m/z found 277.0330.
112.5, 112.3 (CH), 110.7, 46.9 (CH), 36.9 (CH₂), 21.8 (CH₂), 20.9 (CH₂). HR-MS calculated for C₁₂H₁₁NBr: m/z 248.0075, m/z found 248.0077.

**6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-1-amine (5):** Compound 5 was purchased as a 25 mg solid form from Enamine. RP-UPLC: tᵣ = 1.73 min (method A). ¹H NMR (400 MHz, CDCl₃): δ 8.37 (s, 1H, NH), 7.21 (1H, dd, J = 8.8, 4.4 Hz, Hₘᵢ), 7.11 (1H, dd, J = 9.6, 2.6 Hz, Hₘᵢ), 6.88 (1H, td, J = 9.1, 2.5 Hz, Hₘᵢ), 4.09 – 4.05 (1H, m), 2.68 – 2.64 (2H, m), 2.23 – 2.16 (1H, m), 2.07 – 1.99 (1H, m), 1.89 – 1.77 (m, 1H), 1.65 – 1.55 (1H, m). ¹³C NMR (101 MHz, CDCl₃): δ 157.9 (d, J = 234 Hz, CF), 139.2, 132.4, 128.0 (d, J = 10.1 Hz), 111.4 (d, J = 9.1 Hz, CH), 111.2 (d, J = 4 Hz), 109.7 (d, J = 26.3 Hz, CH), 103.5 (d, J = 23.3 Hz, CH), 46.9 (CH), 36.9 (CH₂), 21.8 (CH₂), 20.0 (CH₂). HR-MS calculated for C₁₂H₁₁FN: m/z 188.0876, m/z found 188.0875.

**6-methyl-N-propyl-2,3,4,9-tetrahydro-1H-carbazol-1-amine, TFA salt (6):** Compound 6 was purchased as a 25 mg solid form from Enamine. Compound was purified by preparative HPLC (gradient from 70/30 A/D to 55/45 A/D in 18 minutes, tᵣ = 35 % D) to afford 6 as a white powder. RP-UPLC: tᵣ = 1.94 min (method A). ¹H NMR (400 MHz, CDCl₃): δ 10.01 (1H, s, NH), 9.46 (2H, d, J = 223.2 Hz, NH₂), 7.27 (1H, m, Har), 7.24 (1H, d, J = 8.3 Hz, Hₘᵢ), 7.01 (1H, dd, J = 8.3, 1.7 Hz, Hₘᵢ), 4.63 – 4.58 (1H, m), 2.90 – 2.78 (1H, m), 2.74 – 2.62 (3H, m), 2.43 (3H, s, CH₃), 2.31 – 2.19 (1H, m), 2.12 – 1.97 (1H, m), 1.84 – 1.73 (1H, m), 1.71 – 1.56 (2H, m), 0.88 (3H, t, J = 7.4 Hz, CH₃). ¹³C NMR (101 MHz, CDCl₃): δ 135.2, 129.0, 126.7, 125.7, 124.9 (CH), 118.5 (CH), 115.9, 111.5 (CH), 52.0 (CH), 44.3 (CH₂), 25.5 (CH₂), 21.6 (CH₃), 21.6 (CH₂), 20.7 (CH₂), 20.1 (CH₂), 11.2 (CH₃). HR-MS calculated for C₁₆H₂₃N₂: m/z 243.1853, m/z found 243.1855.

**2,3,4,9-tetrahydro-1H-carbazol-1-ol (7):** Compound 7 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: tᵣ = 2.16 min (method A). ¹H NMR (300 MHz, MeOD): δ 7.40 (1H, dt, J = 7.7, 1.1 Hz, Hₜₙ), 7.30 (1H, dt, J = 8.1, 0.9 Hz, Hₜₙ), 7.05 (1H, ddd, J = 8.2, 7.0, 1.3 Hz, Hₜₙ), 6.95 (1H, ddd, J = 8.0, 7.0, 1.1 Hz, Hₜₙ), 4.89 – 4.85 (1H, m), 2.84 – 2.55 (2H, m), 2.16 – 2.00 (m, 2H), 1.97 – 1.77 (m, 2H). HR-MS calculated for C₁₂H₁₇NO: m/z 186.0924, m/z found 186.0926.

**2,3,4,9-tetrahydro-1H-carbazole-1-carbonitrile (8):** Compound 8 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: tᵣ = 2.33 min (method A). ¹H NMR (300 MHz, MeOD): δ 7.42 (1H, dt, J = 7.7, 1.0 Hz, Hₜₙ), 7.31 (1H, dt, J = 8.1, 0.9 Hz,
H\textsubscript{ar}), 7.10 (1H, ddd, J = 8.2, 7.1, 1.3 Hz, H\textsubscript{ar}), 7.00 (1H, ddd, J = 8.0, 7.1, 1.1 Hz, H\textsubscript{ar}), 4.19 (1H, tt, J = 5.5, 1.4 Hz), 2.87 – 2.58 (2H, m), 2.36 – 2.12 (2H, m), 2.13 – 1.88 (2H, m). HR-MS calculated for C\textsubscript{13}H\textsubscript{11}DN\textsubscript{2}Na: m/z 220.0955, m/z found 220.0956.

(2,3,4,9-tetrahydro-1H-carbazol-1-yl)methanamine (9): Compound 9 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t\textsubscript{R} = 1.71 min (method A). \textsuperscript{1}H NMR (300 MHz, MeOD): δ 7.40 (1H, d, J = 7.7 Hz), 7.29 (1H, d, J = 8.0 Hz), 7.07 (1H, ddd, J = 8.2, 7.1, 1.3 Hz), 6.98 (1H, ddd, J = 8.1, 7.1, 1.1 Hz), 3.47 (1H, dd, J = 12.6, 3.7 Hz), 3.03 – 2.92 (1H, m), 2.88 – 2.62 (2H, m), 3.31 – 3.23 (1H, m), 2.22 – 1.97 (2H, m), 1.96 – 1.69 (2H, m). \textsuperscript{13}C NMR (101 MHz, MeOD): δ 138.1, 132.8, 128.6, 122.5 (CH\textsubscript{ar}), 119.8 (CH\textsubscript{ar}), 118.8 (CH\textsubscript{ar}), 112.4, 111.8 (CH\textsubscript{ar}), 43.9 (CH\textsubscript{2}), 33.8 (CH), 27.7 (CH\textsubscript{2}), 22.1 (CH\textsubscript{2}), 21.9 (CH\textsubscript{2}). HR-MS calculated for C\textsubscript{13}H\textsubscript{17}N\textsubscript{2}: m/z 201.1386, m/z found 201.1391.

1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (10): Compound 10 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t\textsubscript{R} = 1.51 min (method A). \textsuperscript{1}H NMR (300 MHz, MeOD): δ 7.38 (1H, d, J = 7.6 Hz, H\textsubscript{ar}), 7.27 (1H, d, J = 7.9 Hz, H\textsubscript{ar}), 7.06 – 7.00 (1H, m, H\textsubscript{ar}), 6.98 - 6.93 (1H, m, H\textsubscript{ar}), 4.13 (1H, dt, J = 6.7, 1.9 Hz), 3.35 – 3.27 (1H, m), 3.03 - 2.92 (1H, m), 2.88 – 2.62 (2H, m), 1.48 (3H, d, J = 6.7 Hz, CH\textsubscript{3}). \textsuperscript{13}C NMR (101 MHz, MeOD): δ 137.8, 137.7, 128.6, 121.9 (CH\textsubscript{ar}), 119.6 (CH\textsubscript{ar}), 118.6 (CH\textsubscript{ar}), 111.8 (CH\textsubscript{ar}), 108.1, 49.53 (CH), 43.6 (CH\textsubscript{2}), 22.9 (CH\textsubscript{2}), 20.3 (CH\textsubscript{3}). HR-MS calculated for C\textsubscript{12}H\textsubscript{14}DN\textsubscript{2}: m/z 188.129, m/z found 188.1292.

1-(1-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)ethan-1-one (11): Compound 11 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t\textsubscript{R} = 2.00 min (method A). \textsuperscript{1}H NMR (300 MHz, MeOD): δ 7.40 (1H, d, J = 7.6 Hz, H\textsubscript{ar}), 7.33 – 7.24 (1H, m, H\textsubscript{ar}), 7.12 – 6.93 (2H, m, H\textsubscript{ar}), 5.66 (1H, q, J = 6.7 Hz), 5.15 (q, J = 6.7 Hz, 0H), 4.20 – 4.04 (1H, m), 3.52 (1H, ddd, J = 13.9, 10.0, 6.0 Hz), 3.15 – 2.96 (m, 0H), 2.93 – 2.66 (3H, m), 2.23 (4H, d, J = 1.5 Hz), 1.61 (1H, d, J = 6.7 Hz, 1H), 1.48 (2H, d, J = 6.8 Hz, 2H). HR-MS calculated for C\textsubscript{14}H\textsubscript{17}N\textsubscript{2}O: m/z 229.1335, m/z found 229.1331.

1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylic acid (12): Compound 12 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t\textsubscript{R} = 1.31 min (method A). \textsuperscript{1}H NMR (300 MHz, DMSO): δ 10.86 (1H, s), 7.39 (2H, d, J = 8.8 Hz, H\textsubscript{ar}), 7.04 (1H, t, J = 7.4 Hz, H\textsubscript{ar}), 6.95 (1H, t, J = 7.0 Hz, H\textsubscript{ar}), 3.4 – 3.2 (2H, m), 2.86 (2H, q,
$J = 5.8 \text{ Hz}$), 1.71 (3H, s, CH$_3$). HR-MS calculated for C$_{13}$H$_{13}$N$_2$O$_2$: $m/z$ 229.0983, $m/z$ found 229.0986.

1,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole, HCl salt (13): Compound 13 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: $t_R = 1.56$ min (method A). $^1$H NMR (300 MHz, MeOD): $\delta$ 7.47 (1H, dt, $J = 7.8, 1.1 \text{ Hz}$, H$_{ar}$), 7.36 (1H, dt, $J = 8.1, 1.0 \text{ Hz}$, H$_{ar}$), 7.15 (1H, ddd, $J = 8.2, 7.1, 1.3 \text{ Hz}$, H$_{ar}$), 7.06 (1H, ddd, $J = 8.1, 7.1, 1.1 \text{ Hz}$, H$_{ar}$), 4.84 – 4.74 (1H, m), 3.83 – 3.68 (1H, m), 3.16 (1H, ddd, $J = 16.3, 4.7, 1.5 \text{ Hz}$), 2.83 (1H, ddd, $J = 16.4, 11.4, 2.5 \text{ Hz}$), 1.75 (3H, d, $J = 6.8 \text{ Hz}$, CH$_3$), 1.59 (3H, d, $J = 6.5 \text{ Hz}$, CH$_3$). HR-MS calculated for C$_{13}$H$_{16}$N$_2$: $m/z$ 202.1449, $m/z$ found 202.1455.

1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (14): Compound 14 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: $t_R = 1.45$ min (method A). $^1$H NMR (300 MHz, DMSO): $\delta$ 11.05 (1H, s), 7.45 (1H, d, $J = 7.7 \text{ Hz}$, H$_{ar}$), 7.33 (1H, d, $J = 8.0 \text{ Hz}$, H$_{ar}$), 7.14 – 7.05 (1H, m, H$_{ar}$), 7.03 – 6.95 (1H, m, H$_{ar}$), 4.50 (1H, d, $J = 7.0 \text{ Hz}$), 3.59 (1H, dd, $J = 11.9, 4.8 \text{ Hz}$), 3.15 (1H, ddd, $J = 15.9, 4.8 \text{ Hz}$), 2.76 (1H, ddd, $J = 16.0, 11.9, 2.4 \text{ Hz}$), 1.60 (3H, d, $J = 6.7 \text{ Hz}$, CH$_3$). HR-MS calculated for C$_{13}$H$_{15}$N$_2$O$_2$: $m/z$ 231.1128, $m/z$ found 231.1126.

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid (15): Compound 15 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: $t_R = 1.43$ min (method A). $^1$H NMR (300 MHz, DMSO): $\delta$ 10.93 (1H, s), 7.44 (1H, d, $J = 7.7 \text{ Hz}$, H$_{ar}$), 7.33 (1H, d, $J = 8.0 \text{ Hz}$, H$_{ar}$), 7.11 – 7.02 (1H, m, H$_{ar}$), 7.02 – 6.93 (1H, m, H$_{ar}$), 4.30 – 4.10 (2H, m), 3.60 (1H, dd, $J = 10.4, 5.0 \text{ Hz}$), 3.13 (1H, dd, $J = 15.9, 4.8 \text{ Hz}$), 2.81 (1H, ddd, $J = 16.2, 5.0 \text{ Hz}$), 1.60 (3H, d, $J = 6.7 \text{ Hz}$, CH$_3$). HR-MS calculated for C$_{12}$H$_{13}$N$_2$O$_2$: $m/z$ 217.0972, $m/z$ found 217.0970.

methyl 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (16): Compound 16 was purchased as a 25 mg solid form from Princeton Biomolecular Research. Compound was purified by preparative HPLC (gradient from 90/10 A/D to 70/30 A/D in 18 minutes, $t_R = 24$ %) to afford 16 as a white powder. RP-UPLC: $t_R = 1.64$ min (method A). $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ 8.89 (1H, s, NH), 7.45 – 7.39 (1H, m, H$_{ar}$), 7.24 (1H, t, $J = 1.1 \text{ Hz}$, H$_{ar}$), 7.19 – 7.11 (2H, m), 4.52 (1H, d, $J = 15.7 \text{ Hz}$), 4.26 (1H, d, $J = 15.7 \text{ Hz}$), 4.14 (1H, dd, $J = 9.3, 5.5 \text{ Hz}$), 3.75 (3H, s, CH$_3$), 3.39 – 3.11 (2H, m). $^{13}$C NMR (101 MHz, CDCl$_3$): $\delta$ 168.7, 136.8, 126.0, 125.2, 122.9 (CH$_{ar}$), 120.1 (CH$_{ar}$), 118.2 (CH$_{ar}$), 111.8 (CH$_{ar}$), 105.2, 54.9 (CH), 53.6 (CH$_3$), 40.7 (CH$_2$), 22.2 (CH$_2$). HR-MS calculated for C$_{13}$H$_{15}$N$_2$O$_2$: $m/z$ 231.1128, $m/z$ found 231.1132.
6-methyl-2,3,4,9-tetrahydro-1H-carbazol-3-amine (17): Compound 17 was purchased as a 25 mg solid form from Enamine. RP-UPLC: t_R = 1.67 min (method A). ^1H NMR (400 MHz, CDCl_3): δ 7.62 (1H, s, NH), 7.23 (1H, m, H_ar), 7.16 (1H, d, J = 8.2 Hz, H_ar), 6.94 (1H, dd, J = 8.2, 1.6 Hz, H_ar), 3.29 (1H, dddd, J = 9.8, 8.2, 5.1, 3.0 Hz), 3.07 – 2.95 (1H, m), 2.86 – 2.77 (2H, m), 2.48 – 2.38 (4H, m), 2.15 – 1.99 (1H, m), 1.79 (1H, ddt, J = 12.7, 9.8, 7.7 Hz), 1.52 (2H, s, NH_2). ^13C NMR (101 MHz, CDCl_3): δ 134.7, 133.3, 128.6, 128.1, 122.8 (CH_ar), 117.7 (CH_ar), 110.2 (CH_ar), 108.3, 48.0 (CH), 32.9 (CH_2), 31.4 (CH_2), 21.8 (CH_2), 21.6 (CH_3). HR-MS calculated for C_{13}H_{18}DN_2: m/z 204.1606, m/z found 204.1605.

3-(tert-butyl)-2,3,4,9-tetrahydro-1H-carbazole (18): Compound 18 was purchased as a 25 mg solid form from Princeton Biomolecular Research. ^1H NMR (300 MHz, DMSO): δ 10.58 (1H, s, NH), 7.33 (1H, d, J = 7.5 Hz, H_ar), 7.25 – 7.17 (1H, m, H_ar), 6.96 (1H, td, J = 7.9, 7.5, 1.4 Hz, H_ar), 6.90 (1H, td, J = 7.3, 1.3 Hz, H_ar), 2.85 – 2.59 (3H, m), 2.37 – 2.23 (1H, m), 2.14 – 1.98 (1H, m), 1.59 – 1.28 (2H, m), 0.98 (9H, s, tBu). HR-MS calculated for C_{16}H_{21}N: m/z 228.1747, m/z found 228.1705.

2-ethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (19): Compound 19 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t_R = 1.55 min (method A). ^1H NMR (300 MHz, MeOD): δ 7.38 – 7.31 (1H, m, H_ar), 7.26 – 7.17 (1H, m, H_ar), 7.03 (1H, ddd, J = 8.1, 7.1, 1.4 Hz, H_ar), 6.96 (1H, ddd, J = 8.2, 7.1, 1.2 Hz, H_ar), 3.71 (2H, d, J = 1.5 Hz), 2.92 (4H, s), 2.73 (2H, q, J = 7.2 Hz), 1.25 (3H, t, J = 7.2 Hz, CH_3). HR-MS calculated for C_{13}H_{16}DN_2: m/z 202.1449, m/z found 202.1451.

2,6-dimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (20): Compound 20' was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t_R = 1.55 min (method A). ^1H NMR (300 MHz, MeOD) δ 7.25 (1H, ddd, J = 6.9, 2.1 Hz, H_ar), 7.06 – 6.84 (2H, m, H_ar), 4.51 (2H, s), 3.71 (2H, s), 3.25 (2H, t, J = 6.3 Hz), 3.12 (3H, s, CH_3), 2.47 (3H, s, CH_3). HR-MS calculated for C_{13}H_{16}D_2N_2: m/z 203.1512, m/z found 203.1514.

2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole (21): Compound 21 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: t_R = 1.43 min (method A). ^1H NMR (300 MHz, MeOD): δ 7.35 – 7.31 (1H, m, H_ar), 7.26 (1H, dt, J = 8.0, 1.0 Hz, H_ar), 7.06 – 6.92 (2H, m, H_ar), 3.68 (2H, t, J = 1.5 Hz), 2.98 – 2.81 (4H, m), 2.54 (3H, s, CH_3). HR-MS calculated for C_{12}H_{14}DN_2: m/z 188.1293, m/z found 188.1293.
1,2,4-trimethyl-1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridin-8-amine (22): Compound 22 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 1.00 \) min (method A). \(^1\)H NMR (300 MHz, MeOD): \( \delta 7.27 \) (1H, d, \( J = 8.7 \) Hz, \( H_{ar} \)), 6.92 (1H, d, \( J = 2.2 \) Hz, \( H_{ar} \)), 6.78 (1H, dd, \( J = 2.3 \) Hz, \( H_{ar} \)), 6.25 (2H, s, NH), 4.71 – 4.56 (1H, m), 3.79 (1H, dd, \( J = 12.2, 5.5 \) Hz), 3.52 – 3.39 (1H, m), 3.29 – 3.23 (1H, m), 3.08 (3H, s, \( CH_3 \)), 1.79 (3H, d, \( J = 6.7 \) Hz, \( CH_3 \)), 1.39 (3H, d, \( J = 6.8 \) Hz, \( CH_3 \)). HR-MS calculated for \( C_{14}H_{19}N_2O: m/z \) 231.1492, \( m/z \) found 231.1492.

3-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (23): Compound 23 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 2.27 \) min (method B). \(^1\)H NMR (300 MHz, CDCl\(_3\)): \( \delta 8.00 – 7.83 \) (1H, m), 7.49 (1H, d, \( J = 7.0 \) Hz), 4.51 – 4.26 (1H, m), 4.26 – 4.01 (1H, m), 3.86 – 3.62 (1H, m), 2.92 (1H, dd, \( J = 18.4, 9.9 \) Hz), 2.42 – 2.12 (2H, m), 2.02 – 1.77 (1H, m), 1.25 (3H, t, \( J = 5.9 \) Hz). MS calculated for \( C_{12}H_{15}N_2: m/z \) 187.12, \( m/z \) found 187.03.

3,4-dihydro-2\(H\)-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol (24): Compound 24 was purchased as a 25 mg solid form from Princeton Biomolecular Research. RP-UPLC: \( t_R = 1.20 \) min (method A). \(^1\)H NMR (300 MHz, MeOD): \( \delta 7.49 – 7.43 \) (1H, m, \( H_{ar} \)), 7.41 – 7.34 (1H, m, \( H_{ar} \)), 7.21 (2H, dd, \( J = 6.0, 3.2 \) Hz, \( H_{ar} \)), 4.65 – 4.55 (1H, m), 4.34 – 4.10 (2H, m), 3.45 (1H, ddd, \( J = 12.8, 2.5, 0.9 \) Hz), 3.29 – 3.21 (1H, m). HR-MS calculated for \( C_{10}H_{11}N_2S: m/z \) 207.0587, \( m/z \) found 207.0588.

(S)-6-chloro-N-((S)-1-(4-methoxyphenyl)ethyl)-2,3,4,9-tetrahydro-1\(H\)-carbazol-1-amine, HCl salt ((S)-26): 6-chloro-2,3,4,9-tetrahydrocarbazol-1-one (282 mg, 1.3 mmol, 1.0 eq) was suspended in dry toluene (4 mL) under argon. (1S)-1-(4-methoxyphenyl)ethanamine (0.2 mL, 1.3 mmol, 1.0 eq) and HCl conc (10 \( \mu \)L) were added in presence of activated 4A molecular sieves. The mixture was stirred at 112 °C during 6 h before it was allowed to cool down to room temperature. The mixture was added dropwise to a solution of NaBH\(_4\) (48 mg, 1.3 mmol, 1.0 eq) in ethanol (3.4 mL) at - 30 °C. The flask was washed twice with 0.5 mL of dried toluene. The mixture was stirred at -30 °C for 14.5 h before warming up slowly at room temperature. Acetone (1 mL) was added and the solution was stirred at room temperature for 30 minutes before the removal of few milliliters of solvent. Ethyl acetate and water were added. The two phases were separated. The aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed with water, then with brine, dried over Na\(_2\)SO\(_4\) and concentrated. The yellow oil was then dissolved in toluene (2 mL) and cooled down to - 5 °C.
1.4 mL HCl (1.25 M in MeOH) were added and the solution was stirred at -5 °C for 30 minutes. The white precipitate was filtered, washed with TBME and dried in vacuo to afford (S)-26 (297 mg, 0.76 mmol, 59%) as a white solid, βD = -9.5 (c 0.055, MeOH). RP-UPLC: tR = 4.61 min (method B). ¹H NMR (400 MHz, DMSO): δ 11.75 (1H, s), 9.87 (1H, d, J = 10.0 Hz), 9.24 (1H, dd, J = 12.0, 6.4 Hz), 7.71 (2H, d, J = 8.5 Hz), 7.52 (1H, d, J = 2.1 Hz), 7.41 (1H, d, J = 8.6 Hz), 7.14 (1H, dt, J = 8.7, 4.3 Hz), 6.99 (2H, d, J = 8.7 Hz), 4.70 (1H, q, J = 6.4 Hz), 4.65 – 4.49 (1H, m), 3.76 (3H, s), 2.64 (2H, q, J = 6.0, 5.5 Hz), 2.18 – 2.08 (1H, m), 2.04 – 1.90 (2H, m), 1.86 – 1.68 (1H, m), 1.67 (3H, d, J = 6.7 Hz). ¹³C NMR (101 MHz, DMSO): δ 159.6, 134.4, 130.0, 129.7, 129.5 (CHar), 128.9, 128.2, 127.1, 123.5, 122.2 (CHar), 117.8 (CHar), 114.1 (CHar), 113.1, 113.0 (CHar), 55.2 (CH), 55.2 (CH), 49.1 (CH₃), 25.9 (CH₂), 20.1 (CH₂), 19.5 (CH₃), 18.9 (CH₃). HR-MS calculated for C₂₁H₂₄N₂OCl: m/z 355.1572, m/z found 355.1577.

(R)-6-chloro-N-((R)-1-(4-methoxyphenyl)ethyl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine, HCl salt ((R)-26): The procedure described above for (S)-26 starting with (1R)-1-(4-methoxyphenyl)ethanamine (0.2 mL, 1.3 mmol, 1.0 eq) afforded (R)-7 (328 mg, 0.84 mmol, 66%) as a white solid. βD = +10.2 (c 0.055, MeOH). RP-UPLC: tR = 4.61 min (method B). ¹H NMR (400 MHz, DMSO): δ 11.75 (1H, s), 9.87 (1H, d, J = 10.0 Hz), 9.24 (1H, dd, J = 12.0, 6.4 Hz), 7.71 (2H, d, J = 8.5 Hz), 7.52 (1H, d, J = 2.1 Hz), 7.41 (1H, d, J = 8.6 Hz), 7.14 (1H, dt, J = 8.7, 4.3 Hz), 6.99 (2H, d, J = 8.7 Hz), 4.70 (1H, q, J = 6.4 Hz), 4.65 – 4.49 (1H, m), 3.76 (3H, s), 2.64 (2H, q, J = 6.0, 5.5 Hz), 2.18 – 2.08 (1H, m), 2.04 – 1.90 (2H, m), 1.86 – 1.68 (1H, m), 1.67 (3H, d, J = 6.7 Hz). ¹³C NMR (101 MHz, DMSO): δ 159.6, 134.4, 130.0, 129.7, 129.5 (CHar), 128.9, 128.2, 127.1, 123.5, 122.2 (CHar), 117.8 (CHar), 114.1 (CHar), 113.1, 113.0 (CHar), 55.2 (CH), 55.2 (CH), 49.1 (CH₃), 25.9 (CH₂), 20.1 (CH₂), 19.5 (CH₃), 18.9 (CH₃). HR-MS calculated for C₂₁H₂₄N₂OCl: m/z 355.1572, m/z found 355.1581.
HPLC purity of final compounds

Table 1: Purity of the final compounds

| Compound | Retention time | Purity [%] | HPLC Method<sup>a</sup> |
|----------|----------------|------------|--------------------------|
| 1<sup>a</sup> | 4.67 min | 99 | B |
| 1<sup>b</sup> | 2.24 min | 97 | A |
| 1<sup>c</sup> | 2.41 min | 99 | A |
| 1<sup>d</sup> | 1.43 min | 99 | A |
| 1<sup>e</sup> | 1.48 min | 99 | A |
| 1<sup>f</sup> | 1.72 min | 99 | A |
| 1<sup>g</sup> | 1.78 min | 99 | A |
| 1<sup>h</sup> | 1.89 min | 99 | A |
| 1<sup>i</sup> | 1.17 min | 98 | A |
| 1<sup>j</sup> | 1.73 min | 99 | A |
| 1<sup>k</sup> | 1.11 min | 99 | A |
| 1<sup>l</sup> | 2.30 min | 99 | A |
| 1<sup>m</sup> | 1.90 min | 87 | A |
| 1<sup>n</sup> | 1.83 min | 99 | A |
| 2<sup>a</sup> | 2.21 min | 99 | A |
| rac<sup>3</sup> | 1.83 min | 99 | A |
| (S)-3<sup>a</sup> | 1.85 min | 99 | A |
| (R)-3<sup>a</sup> | 1.84 min | 98 | A |
| 4<sup>a</sup> | 1.89 min | 99 | A |
| 5<sup>a</sup> | 1.73 min | 99 | A |
| 6<sup>a</sup> | 1.94 min | 99 | A |
| 7<sup>a</sup> | 2.16 min | 99 | A |
| 8<sup>a</sup> | 2.33 min | 99 | A |
| 9<sup>a</sup> | 1.71 min | 99 | A |
| 10<sup>a</sup> | 1.51 min | 99 | A |
| 11<sup>a</sup> | 2.00 min | 99 | A |
| 12<sup>a</sup> | 1.31 min | 99 | A |
| 13<sup>a</sup> | 1.56 min | 99 | A |
| 14<sup>a</sup> | 1.45 min | 99 | A |
| 15<sup>a</sup> | 1.43 min | 90 | A |
| 16<sup>a</sup> | 1.64 min | 99 | A |
| 17<sup>a</sup> | 1.67 min | 99 | A |
| 18<sup>b</sup> | ND<sup>b</sup> | ND<sup>b</sup> | A |
| 19<sup>a</sup> | 1.55 min | 99 | A |
| 20<sup>a</sup> | 1.55 min | 99 | A |
| 21<sup>a</sup> | 1.43 min | 99 | A |
| 22<sup>a</sup> | 1.00 min | 96 | A |
| 23<sup>a</sup> | 2.27 min | 99 | B |
| 24<sup>a</sup> | 1.20 min | 99 | A |

<sup>a</sup> method A: from 100 % A to 100 % D in 2.2 min, then 100 % D. Method B: from 100 % A to 100% D in 7.5 min, then 100 % D. <sup>b</sup> ND = Not Determined. The compound was not soluble in acetonitrile/water.
$^1$H and $^{13}$C NMR spectra

![NMR Spectra Image]

1a
Complexation attempts with rac-3

A stock solution of (NH₄)₂Fe(SO₄)₂•6 H₂O (0.45 M) in D₂O was prepared. The compound rac-3 was dissolved in D₂O to form a 6.4 mM solution in the NMR tube. Then, stock solution was successively added to result in 0.5, 1, 2, 5, 10 equivalents of Fe(II). Before each measurement, the NMR tube was shaken for 30 s. No shifts of the ¹H NMR signals of 3, potentially indicating complexation by iron, could be detected.
Selected IC$_{50}$ curves for inhibition of ZIP8

Figure S2. Representative IC$_{50}$ curves for rac-3 analogues (a) and enantiomers (b) in ZIP8 transiently transfected HEK293T cells. Cd$^{2+}$-uptake (5µM) was measured as the Area Under the curve (AUC) in the presence of the indicated compound concentrations using the Calcium 5 fluorescent dye. Each data point represents the Mean ± SD (N=6-8) of the AUC determined in the presence of each compound concentration. IC$_{50}$ values were calculated from 2 independent experiments performed in triplicate and are represented as the Mean ± SD (N=4-6). See Methods for details.